Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
Introduction
This publication presents the data and findings of the risk assessment on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-MMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.
Download as PDF
Table of contents
- Acknowledgements
- Foreword
- EMCDDA Initial Report on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC)
- Risk assessment report on a new psychoactive substance: 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC)
- Annex 1: Technical report on the new psychoactive substance 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC)
- Annex 2: Participants of the risk assessment meeting, 18 November 2021
Issue:
34
Pages:
131
Price:
Free
ISBN:
978-92-9497-706-9
ISSN:
1725-4493
Pub. DOI:
10.2810/71344
Catalog Number:
TD-AK-22-004-EN-N
Main subject
Target audience